Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23919072 | 0.87 | KDM1A (0.30) | KDM1A | |
| SCHEMBL25608651 | 0.85 | HRH3 (0.34) | HRH3NPC1 | |
| SCHEMBL21421587 | 0.79 | KDM1A (0.41) | KDM1ANPC1WNT1GSK3BDYRK1A | |
| SCHEMBL21673768 | 0.77 | KDM1A (0.39) | KDM1ANPC1 | |
| SCHEMBL22564880 | 0.77 | HRH3 (0.37) | HRH3 | |
| SCHEMBL26445297 | 0.76 | HRH3 (0.40) | HRH3 | |
| SCHEMBL12448058 | 0.75 | DAO (0.39) | KDM1AHRH3 | |
| SCHEMBL22924095 | 0.74 | KDM1A (0.39) | KDM1ANPC1WNT1GSK3BDYRK1A | |
| SCHEMBL26058836 | 0.74 | KDM1A (0.39) | KDM1ANPC1WNT1GSK3BDYRK1A | |
| SCHEMBL24845907 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | KDM1A 1766/4885HRH3 2096/4885NPC1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.